Publications by authors named "Ee Ke"

Claim this Profile
P
PDZRN4 suppresses lung adenocarcinoma progression via inhibiting ubiquitin-mediated HIF-1A degradation.
Honghao Li, Junfeng Wu, Hua Dai, Jiaming Li, Xiaoyan Bai, Ee Ke

Oncogene· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study.
Chang Lu, Chong-Rui Xu, Yi-Chen Zhang, E-E Ke, Yue-Li Sun

Biomark Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Fascin1 maintains chondrocytes phenotype and attenuates osteoarthritis development.
Panpan Yang, Yun Xiao, Liangyu Chen, Chengliang Yang, Qinwei Cheng, Ee Ke

Bone Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC.
Yang-Si Li, Wen-Pu Lai, Kai Yin, Mei-Mei Zheng, Hai-Yan Tu, E-E Ke

Cell Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Song Dong, Zhen Wang, Jia-Tao Zhang, Bingfa Yan, Chao Zhang, E-E Ke

JAMA Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.
Si-Yang Maggie Liu, Jie Huang, Jia-Yi Deng, Chong-Rui Xu, Hong-Hong Yan, E-E Ke

Sci Bull (Beijing)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.
Hai-Yan Tu, Kai Yin, Xiaotian Zhao, E-E Ke, Si-Pei Wu

Mol Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
Si-Yang Maggie Liu, Hai-Yan Tu, Xue-Wu Wei, Hong-Hong Yan, Xiao-Rong Dong, E E Ke

Nat Med· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non-small cell lung cancers.
Jia Tao Zhang, Song Dong, Li Yan Ji, Jia Ying Zhou, Zhi Hong Chen, E E Ke

Thorac Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
Hai-Yan Tu, Yang-Si Li, Xiao-Yan Bai, Yue-Li Sun, Ming-Ying Zheng, E-E Ke

Clin Lung Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Filamin A alleviates ovariectomy-induced bone loss in mice via the WNT/β-catenin signaling pathway.
Changsheng Yang, Panpan Yang, Peilin Liu, Hong Wang, Ee Ke

Cell Signal· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.
Qi Zhang, Xu-Chao Zhang, Jin-Ji Yang, Zhen-Fan Yang, Yu Bai, E-E Ke

J Thorac Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
Hai-Yan Tu, E-E Ke, Jin-Ji Yang, Yue-Li Sun, Hong-Hong Yan

Lung Cancer· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R.
E-E Ke, Qing Zhou, Qiu-Yi Zhang, Jian Su, Zhi-Hong Chen

J Thorac Oncol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Qiuyi Zhang, Ee Ke, Feiyu Niu, Wei Deng, Zhihong Chen

Oncotarget· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
E-E -Ke, Yi-Long Wu

Trends Pharmacol Sci· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence.
E-E Ke, Yi-Long Wu

Ther Adv Respir Dis· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distribution and prognosis of uncommon metastases from non-small cell lung cancer.
Fei-Yu Niu, Qing Zhou, Jin-Ji Yang, Wen-Zhao Zhong, Zhi-Hong Chen, E-E Ke

BMC Cancer· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging paradigms in targeted treatments for Asian patients with NSCLC.
E-E Ke, Qing Zhou, Yi-Long Wu

Expert Opin Pharmacother· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis